Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CFSAN funding

This article was originally published in The Tan Sheet

Executive Summary

The Senate Appropriations Committee recommends that FDA's Center for Food Safety & Applied Nutrition receive $5.3 mil. in funding for its Adverse Event Report System in fiscal year 2007 - a figure that is $1 mil. higher than the President's budget request, according to a committee report released June 22. The proposed increase may be related to the June 21 introduction of legislation that would make serious adverse event reporting mandatory for dietary supplement firms. The committee "has recommended funding to continue enforcement of the provisions contained in DSHEA," the report adds. "It is the Committee's intent that these funds be prioritized by the agency to step up activities against products that are clearly in violation of DSHEA." The senators also are "concerned" that dietary supplement good manufacturing practices have not yet been released by FDA and "direct" the agency to issue them. The Agriculture Appropriations bill now heads to the full Senate after being passed by the committee...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel